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Inhibition of lipolysis in Type 2 diabetes
normalizes glucose disposal without change
in muscle glycogen synthesis rates
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ABSTRACT
Suppression of lipolysis by acipimox is known to improve insulin-stimulated glucose disposal, and
this is an important phenomenon. The mechanism has been assumed to be an enhancement
of glucose storage as glycogen, but no direct measurement has tested this concept or its
possible relationship to the reported impairment in insulin-stimulated muscle ATP production.
Isoglycaemic–hyperinsulinaemic clamps with [13C]glucose infusion were performed on Type 2
diabetic subjects and matched controls with measurement of glycogen synthesis by 13CM R S
(magnetic resonance spectroscopy) of muscle. 31P saturation transfer MRS was used to quantify
muscle ATP turnover rates. Glucose disposal rates were restored to near normal in diabetic
subjects after acipimox (6.2+ −0.8 compared with 4.8+ −0.6 mg·kgffm
−1 ·min−1; P<0.01; control
6.6+ −0.5 mg·kgffm
−1 ·min−1; where ffm, is fat-free mass). The increment in muscle glycogen
concentration was 2-fold higher in controls compared with the diabetic group, and acipimox
administration to the diabetic group did not increase this (2.0+ −0.8 compared with 1.9+ −
1.1 mmol/l; P<0.05; control, 4.0+ −0.8 mmol/l). ATP turnover rates did not increase during insulin
stimulation in any group, but a modest decrease in the diabetes group was prevented by lowering
plasma NEFAs (non-esteriﬁed fatty acids; 8.4+ −0.7 compared with 7.1+ −0.5 μmol·g−1 ·min−1;
P<0.05; controls 8.6+ −0.8 μmol·g−1 ·min−1). Suppression of lipolysis increases whole-body
glucose uptake with no increase in the rate of glucose storage as glycogen but with increase in
whole-body glucose oxidation rate. ATP turnover rate in muscle exhibits no relationship to the
acute metabolic effect of insulin.
INTRODUCTION
Suppression of lipolysis by acipimox or nicotinic acid
has long been known to improve meal tolerance and
insulin sensitivity [1,2]. Sustained suppression of plasma
NEFAs (non-esteriﬁed fatty acids) is associated with a
decrease in intramuscular long-chain fatty acyl-CoAs,
and it is believed that this enhances glucose metabolism
via substrate competition [3]. The mechanism for this
interaction is well described, involving control of cellular
glucose uptake in muscle [4]. Both glucose oxidation and
non-oxidative metabolism are involved, and as one of
the original descriptions reported increase in the active
form of glycogen synthase, it has been assumed that
increased rates of glucose storage as glycogen underlie
the phenomenon [2]. However, there is no direct in vivo
evidence that glycogen synthesis rate is enhanced by
NEFAsuppression.Thismechanismisimportantinfully
understanding the insulin resistance of Type 2 diabetes
and evaluating potential interventions.
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Table 1 Characteristics of subjects
Values are means+ −S.E.M. HbA1c, glycated haemoglobin; NS, not signiﬁcant. 1
cal≈4.184 J.
Type 2 diabetic Control
Characteristic group group P value
Gender (male/female) (n)7 / 3 6 / 2
Age (years) 57+ −25 3 + −3N S
BMI (kg/m2) 28.7+ −1.2 28.1+ −1.1 NS
Fat mass (kg) 26.1+ −2.0 26.4+ −1.7 NS
Fat-free mass (kg) 54.7+ −3.8 58.5+ −3.6 NS
Fasting glucose (mmol/l) 7.7+ −0.3 5.1+ −0.1 0.001
Fasting insulin (pmol/l) 93+ −14 49+ −6 0.026
Mean HbA1c (%) 6.6+ −0.2 5.4+ −0.1 0.001
Fasting triacylglycerol 1.6+ −0.2 1.4+ −0.2 NS
(mmol/l)
Average daily energy 2455+ −198 2248+ −76 NS
expenditure (cal)
Average daily steps taken (n) 6160+ −385 5701+ −288 NS
Recently, demonstration of subnormal insulin stim-
ulation of ATP turnover rates in Type 2 diabetes
has been postulated as a basic defect which limits
glucose metabolism [5–8]. It is not known whether
such a defect underlies change in glucose uptake
or glycogen synthesis itself. By employing 31PM R S
(magnetic resonance spectroscopy) together with 13C
spectroscopy to track glycogen metabolism, it is possible
to examine this fundamental problem. In the present
study, we tested the hypothesis that acute suppression of
lipolysis would improve the rate of glucose metabolism
speciﬁcally by increasing muscle glycogen synthesis. The
effect of decreasing fatty acid availability upon muscle
mitochondrial ATP turnover rates was also examined.
MATERIALS AND METHODS
Subjects
Ten subjects with well-controlled Type 2 diabetes (three
females and seven males) and eight physical activity-,
age- and BMI (body mass index)-matched normal
glucose-tolerantsubjects(twofemalesandsixmales)were
studied (Table 1). All subjects were recruited by means of
advertisementandunderwentacompletemedicalhistory,
clinical examination and laboratory tests to exclude
hepatic and renal diseases. Patients with diabetes on
insulin treatment or any oral hypoglycaemic medications
apart from metformin were excluded. The individuals
in the control group had neither a family history of
diabetes nor were taking any medication known to affect
glucose tolerance or insulin sensitivity. All subjects with
diabetes and no control subjects were taking statins.
Normalglucosemetabolismwasconﬁrmedbyastandard
oral 75-g glucose tolerance test. None of the subjects
performed moderate or intense exercise on a regular
basis. Physical activity was assessed over 3 days using
the Body Monitoring System and SenseWear Armband
(BodyMedia®), which provides a measure of total daily
energyexpenditureandnumberofstepstakenperday[9].
The research was carried out in accordance with the De-
claration of Helsinki (2000), and the study protocol was
approvedbytheNewcastleuponTyneEthicsCommittee
No. 2. Informed consent was obtained from all subjects.
Experimental protocol
All subjects refrained from planned physical exertion
during the 3 days preceding the studies and fasted
overnightfor12 hbeforetheexperiments.Metforminwas
withdrawn3 daysbeforeeachexperiment.Type2diabetic
subjects were each studied on two days, 4–8 weeks apart.
Dosesofacipimox(250 mg)weregivenatbaselineand3 h
later, or on the placebo test day, identical placebo tablets
were given in a double blind fashion. The body weight
and lifestyle of the subjects remained unchanged during
the period of the study. Control subjects were studied on
1 day only with administration of placebo tablets.
Isoglycaemic–hyperinsulinaemic clamps
For all experiments, subjects travelled to the MR
(magneticresonance)Centrebytaxiandweretransported
within the centre by wheelchair. At 08:30 h (−270 min),
one cannula was inserted into an antecubital vein
for administration of glucose and insulin. A second
cannula was inserted into the contralateral wrist vein
for blood sampling. Use of a hand-warming device
ensured arterialization of venous blood. Isoglycaemia
was maintained in order to ensure that the true basal
condition of each participant could be observed, and
the entire study was carried out with the subject lying
in the MR scanner. Isoglycaemic–hyperinsulinaemia was
maintained for 150 min using the clamp technique [10].
Insulin (Actrapid; NovoNordisk) was administered as a
primed continuous infusion (40 m-units·m−2 ·min−1).
To inhibit pancreatic hormone secretion, somatostatin
was infused at 0.06 μg·kg−1 of body weight·min−1
(Somatostatin-UCB; UCB-Pharma) from 5 min before
the start of the insulin infusion and continued for the
duration of the clamp. In order to increase sensitivity
of measurement of the glycogen synthesis rate by 13C
MRS, the variable glucose infusion contained 20% [1-
13C]glucose (Cambridge Isotope Laboratories). Whole-
body insulin sensitivity was determined from calculated
whole-body glucose disposal during the last 30 min of
the hyperinsulinaemic glucose clamp [10]. Whole-body
glucose disposal was calculated from glucose infusion
rate [11]. To assess rate of oxidation of infused glucose,
breath samples for 13CO2 measurement were obtained
just before the start of the clamp (0 min), at 15 min,
45 min, 90 min and at the end of the clamp (150 min). As
this measure would be affected by differences in plasma
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Table 2 Plasma enrichment of [13C]glucose (APE)
Values are means+ −S.E.M.
Plasma enrichment of [13C]glucose (APE)
Group Time (min)... 0 1 54 59 0 1 5 0
Control 0 3.79+ −0.37 7.50+ −0.72 12.31+ −0.66 15.15+ −0.70
Diabetes/placebo 0 2.99+ −0.44 6.34+ −0.50 9.65+ −0.60 12.16+ −0.57
Diabetes/acipimox 0 3.81+ −0.40 7.99+ −0.45 11.33+ −0.60 14.18+ −0.63
glucose enrichment, the index of whole-body glucose
oxidation was calculated as the ratio of breath to plasma
13C APE (atom percentage excess) [(breath APE/
plasma APE)×100].
MRS examinations
MR data were acquired using a 3T Achieva scanner
(Philips) with an in-built body coil used for imaging.
A 14-cm diameter surface coil was used for phosphorus
spectroscopy, and a 6-cm diameter 13Cc o i lw i t ha ni n t e g -
ral quad 1H decoupling coil (PulseTeq) was used for 13C
spectroscopy. Subjects remained supine inside the MR
spectrometer with each coil positioned beneath the
widest part of the left calf during each investigation.
The coil position was marked on the leg with indelible
ink. Scout images were acquired to ensure identical
coil positioning on repeat scans. To prevent movement
during each study, the coil was secured in place using
webbing straps around the calf. Analysis of all spectra
was performed with jMRUI (version 3.0) [12] using the
AMARES ﬁtting algorithm [13].
31P MRS was carried out as described previously
[14] and was acquired at baseline from −240 to
−210 min and from −60 to −30 min and twice further
during the isoglycaemic–hyperglycaemic clamp from 15
to 45 min and from 90 to 120 min. For 13CM R S ,t h e
distance between the 13C/1H decoupling coil surface and
the muscle was recorded from scout images. The 13C
pulse power was calibrated to a nominal value of
80◦ in the tissue of interest by observing the power-
dependent variation in signal from a ﬁducial marker
locatedinthecoilhousing,containingasampleexhibiting
a 13C signal with short T1 (213 mM [2-13C]acetone
and 25 mM GdCl3 in water). Spectra showing the
glycogen 1-13C resonance were acquired using a non-
localized 1H-decoupled 13C pulse-acquire sequence [TR
(relaxation time)=200 ms, spectral width=8 kHz, 3000
averages, WALTZ decoupling, nominal tip angle=80◦]
over a 15-min acquisition time. Calibration of 13C
spectra was performed by comparison of in vivo
glycogen 1-13C signal amplitudes with that of a
standard glycogen solution (100 mM glycogen, 70 mM
KCl and 0.05% sodium azide). Quantiﬁcation was
performed by comparison of signal amplitude with those
from a leg-shaped phantom acquired at a range of
separations between coil and phantom, representative
of the separation between coil and muscle due to
skin and subcutaneous fat. The same coils, pulse se-
quences and tip angles as employed for in vivo spectra
were used for acquisition of these calibration data. 13C
MRS spectra were acquired from subjects at baseline
from −205 to −185 min and from −25 to −5 min and
twicefurtherduringtheisoglycaemic–hyperinsulinaemic
clamp from 50 to 70 min and from 130 to 150 min. The
concentrationofmuscleglycogenatbaseline,[Glyc]muscle,




where Sphantom and Smuscle are the signal intensities arising
from glycogen in the phantom and muscle, respectively,
and [Glyc]phantom is the concentration of glycogen in
the phantom (100 mmol/l). The increments in muscle
glycogen concentration at 70 and 150 min of the clamp,
[ Glyc70]a n d[  Glyc150], respectively, were calculated
from the equation reported previously [15]:
[ Glyc70] =
(S70 − S0) × [Glyc0] × f0
S0 × f70
[ Glyc150] =
(S150 − S70) × [Glyc0] × f0
S0 × f150
where S0, S70 and S150 represent the signal intensity of
[13C]glycogen at 0, 70 and 150 min, [Glyc0] is the basal
glycogen concentration in mmol/l. f 0 corresponds to
the natural abundance enrichment of [13C]glycogen at
baseline (1.1%), and f 70 and f 150 correspond to the mean
percentage 13C enrichment of plasma glucose at 70 and
150 min, respectively. Each increment was then added to
the previous concentration and the slope calculated by
linear regression analysis to yield the rate of glycogen
synthesis [16].
Analytical techniques
Plasma glucose concentration was measured by the
glucose oxidase method (YSI glucose analyser). The 13C
enrichment in plasma glucose was determined by gas
chromatography–MS of the pentaacetate derivatives of
plasma glucose after deproteinization and deionization
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as previously described [17]. Plasma insulin levels were
determined using ELISA kits (Dako). The plasma
NEFA concentration was measured on a Roche Cobas
centrifugal analyser using a Wako kit (Wako Chemicals).
Breath 13C enrichments
Breath samples for 13C enrichments were collected at ﬁve
time points during the study. The subjects were asked
to exhale fully through a short straw into a glass tube
(Labco Exetainer). The tube was immediately stoppered.
13C enrichment of breath samples was determined by
continuous ﬂow isotope ratio MS (ABCA system; PDZ
Europa).TheCV(coefﬁcientofvariation)fortheanalysis
was 0.07% and CV for the collection was 0.3%. All
resultsofthe 13Cenrichmentofexpiredairmeasurements
are expressed as APE.
Statistical analysis
Resultsarepresentedasmeans+ −S.E.M.,unlessotherwise
stated. Statistical analyses were performed using SPSS
15.0 software. Statistical comparisons between diabetic
and control groups were performed using a Student’s
t test, whereas the within-group differences were de-
termined using paired Student’s t test where appropriate.
Changes of sequential data within experiments were
evaluated by repeated-measures ANOVA with post
hoc Tukey correction where appropriate. Statistical
signiﬁcance was accepted at P<0.05.
RESULTS
Plasma glucose, insulin and NEFA
concentrations
The experimental conditions necessary to test the
hypothesis were achieved. During the 3-h baseline
observation, plasma glucose concentration remained
steady in the control subjects (5.1+ −0.1 to 5.0+ −
0.1 mmol/l) and gradually fell as expected in the diabetic
subjects (7.7+ −0.3 to 6.5+ −0.3 mmol/l; P=0.002).
As per protocol, plasma glucose concentration was
clamped at 5.0+ −0.1 mmol/l in the control group,
6.6+ −0.2 mmol/l in the diabetes/placebo group and
6.4+ −0.2 mmol/l in the diabetes/acipimox group
respectively (P<0.001 diabetes compared with control;
Figure 1A). Clamp plasma insulin concentrations were
stable at 573+ −18 pmol/l (Figure 1B). Plasma NEFA
concentrations rapidly suppressed below 0.2 mmol/l in
the diabetes/acipimox study (P=0.005) and were stable
and similar in diabetes/placebo and control groups until
commencement of insulin infusion (Figure 1C).
Figure 1 Time course of plasma glucose (A), insulin (B)
and NEFA (C) concentrations during the isoglycaemic–hyper-
insulinaemic clamps in the control, diabetes/placebo and
diabetes/acipimox groups
Values are means+ −S.E.M. () control group; ( ) diabetes/placebo group; ()
diabetes/acipimox group. ∗P <0.05 for diabetes compared with control.
Glucose disposal rates and muscle
glycogen concentrations
During the clamp, the glucose disposal rate was
lower in the diabetes/placebo group compared
with the control group (4.8+ −0.6 compared with
6.6+ −0.5 mg·kgffm
−1 ·min−1,P=0.04;Figure2A;where
ffm, is fat-free mass). Prior suppression of plasma
NEFAs by acipimox brought about a 23% increase in
the glucose disposal rate in the Type 2 diabetic group
(6.2+ −0.8 compared with 4.8+ −0.6 mg·kgffm
−1 ·min−1,
acipimox compared with placebo respectively, P=0.005;
Figure 2A), so that it approached that of the control
group (6.6+ −0.5 mg·kgffm
−1 ·min−1; P=0.72). The
fasting muscle glycogen concentration was similar in
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Figure 2 Glucose infusion rates (A), incremental changes
in muscle glycogen concentration (B) and the ratio of
breath 13CO2 to plasma [13C]glucose APE (C) in the control,
diabetes/placebo and diabetes/acipimox groups
(A) Glucose infusion rates during the ﬁnal 30 min in the isoglycaemic–hyperinsulin-
aemic clamps in the control, diabetes/placebo (D/Placebo) and diabetes/acipimox
(D/Acipimox) groups. (B) Incremental changes in muscle glycogen concentration
in the three studies. (C) Ratio of breath 13CO2 to plasma [13C]glucose APE at the
end of the each study. ∗P <0.05 and ∗∗P <0.005.
all three groups (diabetes/placebo, 67.5+ −4.5 mmol/l;
diabetes/acipimox, 69.0+ −2.1 mmol/l; and control,
71.1+ −2.6 mmol/l) and remained unchanged during
the basal period. The increment in muscle glycogen
concentration after 70 min of insulin stimulation was
small and not signiﬁcantly different between the three
groups. By the end of the clamp, insulin-stimulated
muscle glycogen concentration increased by +4.0+ −
0.8 mmol/l in the control group and +1.9+ −1.0 mmol/l
in the diabetes/placebo group (P<0.05; Figure 2B).
Prior administration of acipimox did not change the
increment in muscle glycogen (+2.0+ −0.8 mmol/l;
Figure 3 ATP turnover rate in the control, diabetes/placebo
and diabetes/acipimox groups during basal period and after
120 min of isoglycaemic–hyperinsulinaemia
White bar, control group; hatched bar, diabetes/placebo group; black bar,
diabetes/acipimox group. ∗P <0.05.
Figure 2B). The mean rate of muscle glycogen synthesis
from 70 to 150 min was 40+ −7 μmol·l−1 ·min−1 in
the control subjects, 19+ −9 μmol·l−1 ·min−1 in the
diabetes/placebo group and 22+ −7 μmol·l−1 ·min−1
in the diabetes/acipimox group (P<0.05 for control
compared with both diabetes groups).
Breath 13C enrichments
13C APE in expired breath increased during the clamp
in all groups (control, 0.23+ −0.04 and 0.44+ −0.05;
diabetes/placebo, 0.14+ −0.01 and 0.31+ −0.03; dia-
betes/acipimox, 0.22+ −0.02 and 0.44+ −0.03 at 90 and
150 min respectively). In order to compare rates
of glucose oxidation corrected for plasma glucose
enrichment, the ratio of breath to plasma 13CA P Ew a s
examined. At the end of the clamp period, this index
of glucose oxidation was 2.53+ −0.17 compared with
3.16+ −0.21 for diabetes/placebo and diabetes/acipimox
respectively (P<0.005), and 2.87+ −0.24 for controls
(Figure 2C).
Muscle ATP turnover rate
BaselineATPturnoverrateinthediabetes/placebogroup
(8.6+ −0.8 μmol·g−1 of muscle·min−1) was similar to
that of the control subjects (8.6+ −0.7 μmol·g−1 of
muscle·min−1; Figure 3). Muscle ATP turnover rate
in the control group did not change during the basal
period or during the insulin infusion (end of clamp:
8.6+ −1.3 μmol·g−1 ofmuscle·min−1).Agradualdecline
in ATP turnover rate was observed during the course of
the diabetes/placebo group. This decline was not seen in
the diabetes/acipimox group such that by the end of the
clamp, ATP turnover rate was signiﬁcantly higher than
in the diabetes/placebo group (8.4+ −0.7 compared with
7.1+ −0.5 μmol·g−1 of muscle ·min−1; P=0.02).
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DISCUSSION
The results of the present study demonstrate that prior
suppression of lipolysis effectively normalizes glucose
infusionrateduringhyperinsulinaemiainType2diabetes,
but has no effect upon the rate of muscle glycogen
synthesis. In contrast, the subnormal rate of whole-body
glucose oxidation in Type 2 diabetes was increased. The
muscle ATP turnover rate was found to be normal in
Type 2 diabetes but could be modulated to a degree by
suppression of lipolysis.
In Type 2 diabetes, insulin-stimulated whole-body
glucose uptake was observed to be associated with a 2-
fold lower incorporation of [13C]glucose into glycogen.
Acipimox brought about a 23% increase in glucose
infusion rate during hyperinsulinaemia, similar to that
reported by others [2,3]. Previously observed increases
in glucose disposal rates during acipimox administration
have been attributed to change in rate of glycogen
synthesis [18,19]. Clearly, this was not the case over
the 6 h of NEFA suppression in the present study,
a period which has been shown to be sufﬁcient for
the effect upon glucose metabolism to be maximal
[4]. The concept that the synthesis rate of glycogen
would be increased under such circumstances derives
from observation of an increase in the active form of
muscle glycogen synthase, even though no change in
muscle glycogen concentrations could be detected [2].
Subsequently, it has been demonstrated that change in
activation state of glycogen synthase by suppression of
lipolysis occurs in the absence of change in the proximal
steps of insulin activation of glycogen synthase [GSK3β
(glycogen synthase kinase 3β)a n dA k tT h r 308][ 1 9 ] ,a n d
its relevance to substrate ﬂux must be questioned.
Glucose infusion rate is a useful independent measure
ofoverallglucosedisposal,butdoesnottakeintoaccount
possible incomplete suppression of hepatic glucose
production during the clamp. An estimate of endogenous
glucose production can be obtained from the measured
isotopicenrichmentsofinfusateandplasmatogetherwith
glucose infusion rate [20]. Hepatic glucose production
was 0.01, 1.13 and 0.39 mg·kgffm
−1 ·min−1 in control,
diabetes/placebo and diabetes/acipimox groups. By
adding this value to the glucose infusion rate, total
glucose disposal rates can be estimated to be 6.61, 5.93
and 6.59 mg·kgffm
−1 ·min−1 respectively. Hence aci-
pimox brought about an 11% increase in total glucose
disposal. Isoglycaemic–hyperinsulinaemic clamps were
used in the present study in order to observe the
physiological mechanisms operating at ambient plasma
glucose concentrations in the diabetic and control
subjects, and in respect of the primary comparison
between acipimox and placebo studies in the diabetic
subjects, clamp glucose levels were similar.
Whole-body glucose oxidation rate was increased
approximately 25% by acipimox administration. This
could not be quantiﬁed using indirect calorimetry in
the present study as subjects remained in the 3T
magnet throughout the test periods. However, the extent
of acipimox-induced change in glucose oxidation has
previously been shown to be approximately one-third of
the simultaneous change in rate of whole-body glucose
uptake [2]. It is likely that processes additional to glucose
oxidation and muscle glycogen synthesis could explain
the change in whole-body glucose uptake. Glycolysis
with lactate release (Cori cycle activity) could account
for some of the change. Approximately 15% of a glucose
load is taken upbyskeletal musclethen releasedas lactate
in normal health [21] and accounts for approximately
45% of systemic lactate appearance [22]. In Type 2
diabetes, the proportion of glucose taken up by muscle
then released as lactate is 2–3-fold higher than normal
during hyperinsulinaemia [23,24]. This ﬂux could be
affected if early steps in glucose metabolism were rate
limiting,sothattheincreasedtransportofglucoseintothe
muscle cell by low fatty acid availability caused increased
export from muscle as lactate, and an 18% increase in
plasmalactatehasbeenobservedtoaccompanyacipimox-
induced suppression of lipolysis during a clamp [25].
Furtherworkisrequiredtoexaminespeciﬁcallytheacute
changes in glycolysis and glucose oxidation in response
to change in NEFA supply.
Although the change in plasma NEFAs is a useful
general indicator of rate of lipolysis, suppression
of lipolysis would be expected to exert greatest
effect upon muscle metabolism by preventing break-
down of intramyocellular triacylglycerol (triglyceride)
and decreasing intracellular availability of fatty acid and
diacylglycerols. Evidence is accumulating for diacylgly-
cerolstobemajormodulatorsofsubstratelevelcontrolof
metabolism [26,27]. In the present study, the overweight
control subjects were not restudied with acipimox, and
although it would appear likely that similar effects would
be produced, this awaits experimental veriﬁcation.
No signiﬁcant abnormality in muscle ATP turnover
rate in overnight fasting Type 2 diabetic subjects
in comparison with exercise-, weight-, age- and sex-
matched non-diabetic subjects was observed in the
present study, and this contrasts with reports of
decreased basal mitochondrial function in Type 2
diabetes [28,29]. Matching for daily physical activity
may be of importance, as the greatest deﬁcits in ATP
turnover rates have been reported in a study which
explicitly compared extremes of insulin sensitivity with
no matching for habitual physical activity [8]. Both
basal ATP turnover rates and the independently assessed
phosphocreatine recovery times have been reported to be
normal in Type 2 diabetes when compared with exercise-
matched controls [30,31]. However, the major reason
for the apparent discrepancy is clear from the work
of Schrauwen-Hinderling and co-workers [28,29], who
demonstrated that in vivo basal mitochondrial function
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was related to fasting blood glucose, with normal values
for diabetic subjects at levels similar to those reported
in the present study. More recent work from the same
group demonstrated that change in metabolic state alters
measured mitochondrial function [32]. In the Type 2
diabetic subjects given placebo, a fall in muscle ATP
turnover rate was observed during the fasting fall in
plasma glucose concentration. It is possible that the
downward trend occurred with increasing duration of
fasting and consequent increased mobilization of fatty
acids from IMCL (intramyocellular lipid) as acipimox
administration prevented the fall in ATP turnover rate
and would have inhibited intracellular lipolysis. This
phenomenon requires further study.
The present study was designed in the expectation
of inducing an increase in ATP turnover rate with
insulin in the non-diabetic control subjects, as it was
believed that increase in ATP turnover rates would
precede or accompany the acute changes in cellular
metabolism. We observed no effect of insulin upon
ATP turnover rates. However, the previously reported
insulin effect on mitochondrial function related to
measurements averaged over 150 to 350 min of insulin
stimulation [7,33–35]. The method of quantifying ATP
turnover used in the present study was optimized
so that measurements could be carried out frequently
over 30-min periods for the ﬁrst time. When it
became clear that there was no stimulation of ATP
turnover rates in the matched control subjects of the
present study, a separate investigation of time course of
stimulation of muscle ATP turnover rates was conducted
and has been published [14]. We observed no change
in ATP turnover rate during the ﬁrst 45 min of insulin
infusion when the change in glucose metabolism was
maximal, yet in young insulin-sensitive subjects, there
was a slow steady increase evident after 2 h. This
substudy concluded that the acute metabolic effect of
insulin does not depend upon measureable increases in
ATP turnover rate. Processes separate from the insulin
effect on glucose metabolism, such as the insulin effect
on mitochondrial fusion and proliferation [36,37] or
mitochondrial protein synthesis [38], may affect ATP
turnover rate on a timescale of several hours of insulin
stimulation. These processes are temporally dissociated
from and not relevant to the early metabolic effects
of insulin and led to the belief that insulin acutely
changes ATP turnover. However, suppression of plasma
NEFAs in the Type 2 diabetic subjects during the
5.5-h protocol did modestly affect the rate of ATP
turnover, and the converse ﬁnding of elevation of plasma
NEFAs and suppression of ATP turnover has been
reported previously [34]. Other recent work has
demonstrated decreased glucose disposal during short-
term elevation of plasma NEFAs without change in ATP
turnover rate in healthy subjects [35], and the time course
of change in fatty acid supply requires further study.
Overall, change in metabolic state rather than diabetes
can affect measured ATP turnover rates in muscle.
As all subjects with Type 2 diabetes were taking statin
therapy, reﬂecting current clinical practice, the possible
effect of this on glucose metabolism must be considered.
Statins do not affect glucose tolerance nor modulate 72-
h glucose proﬁles, but may bring about a very small
beneﬁcial effect on insulin sensitivity, as shown in a
randomized crossover study designed for this purpose
[39]. No impact of statins would be expected on the
primary comparison of acipimox or placebo exposure
within the diabetic group.
The results of the present study demonstrate that
lowering fatty acid availability increased whole-body
glucose uptake without increasing the rate of glucose
storage as glycogen, but with increase in whole-body
glucoseoxidationrates.AchangeinfastingATPturnover
rate in muscle was observed after suppression of lipolysis
in Type 2 diabetes, but this change was associated with
no effect on muscle glycogen synthesis.
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